Study of immuneresponse after vaccination against SARS-COV-2

Phase 1

• Conditions: immuneresponse after vaccination; Therapeutic area: Body processes [G] - Immune system processes [G12]

• Registration Number: EUCTR2021-001304-15-BE
• Lead Sponsor: vzw az groeninge

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2021-03-16
• Last Update Posted: 13 November 2023

Recruitment & Eligibility

• Status: Authorised-recruitment may be ongoing or finished
• Sex: All
• Target Recruitment: 85

Inclusion Criteria

healthy volunteer older than 18 years
no infections at the time of vaccination and first blooddraw
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 80
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 5

Exclusion Criteria

individuals infected with SARS-CoV-2 or have already been through a SARS-CoV-2 infection
individuals with primary immunedeficiency.
Individuals with immune modulating treatment
individuals with an anuto immune disease
pregnancy

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified